hydrochlorothiazide has been researched along with Apnea, Obstructive Sleep in 3 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-four patients with hypertension and severe OSA (apnea/hypopnea index > 30) received stepped dose titration of antihypertensive treatment, consisting of valsartan 160 mg + amlodipine 5-10 mg + hydrochlorothiazide 25 mg." | 5.17 | Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. ( Aksenova, AV; Chazova, IE; Elfimova, EM; Galitsin, PV; Litvin, AY; Rogoza, AN; Sukmarova, ZN, 2013) |
| "We compared the effects of atenolol (50 mg), amlodipine (5 mg), enalapril (20 mg), hydrochlorothiazide (25 mg), and losartan (50 mg) given in once-daily oral doses on office and ambulatory blood pressures (BPs) in patients with hypertension and obstructive sleep apnea (OSA)." | 5.09 | Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. ( Grote, L; Hedner, J; Kraiczi, H; Peker, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jenner, R | 1 |
| Fatureto-Borges, F | 1 |
| Costa-Hong, V | 1 |
| Lopes, HF | 1 |
| Teixeira, SH | 1 |
| Marum, E | 1 |
| Giorgi, DAM | 1 |
| Consolim-Colombo, FM | 1 |
| Bortolotto, LA | 1 |
| Lorenzi-Filho, G | 1 |
| Krieger, EM | 1 |
| Drager, LF | 1 |
| Litvin, AY | 1 |
| Sukmarova, ZN | 1 |
| Elfimova, EM | 1 |
| Aksenova, AV | 1 |
| Galitsin, PV | 1 |
| Rogoza, AN | 1 |
| Chazova, IE | 1 |
| Kraiczi, H | 1 |
| Hedner, J | 1 |
| Peker, Y | 1 |
| Grote, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension[NCT00801671] | Phase 3 | 50 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for hydrochlorothiazide and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Pressure; Blo | 2013 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2000 |
1 other study available for hydrochlorothiazide and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Association of obstructive sleep apnea with arterial stiffness and nondipping blood pressure in patients with hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2017 |